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Permanent Pancreatic Duct Occlusion With Neoprene-based
Glue Injection After Pancreatoduodenectomy at
High Risk of Pancreatic Fistula
A Prospective Clinical Study
Vincenzo Mazzaferro, MD, PhD,yY Matteo Virdis, MD,y Carlo Sposito, MD,y Christian Cotsoglou, MD,y
Michele Droz Dit Busset, MD,y Marco Bongini, MD, MSc,y Maria Flores, MD, MSc,y
Natalie Prinzi, MD,z and Jorgelina Coppa, MDy
Objective: The aim of this study was to assess safety and efficacy of
pancreatic duct occlusion (PDO) with neoprene-based glue in selected
patients undergoing pancreatoduodenectomy (PD) at high risk of postopera-
tive pancreatic fistula (POPF).
Background Data: PD is the reference standard approach for tumors of the
pancreaticoduodenal region. POPF is the most relevant complication after PD.
PDO has been proposed as an alternative to anastomosis to manage the
pancreatic stump.
Methods: A single-center, prospective, nonrandomized trial enrolled 100
consecutive PD for cancer. Patients at high risk for POPF according to Fistula
Risk Score (FRS) >15% (6 points) were treated with PDO using neoprene
glue (study cohort); patients with FRS 15% (5 points) received pancrea-
ticojejunal anastomosis (PJA: control cohort). Primary endpoint was complica-
tion rate grade 3 according to Dindo–Clavien Classification (DCC). Other
postoperative outcomes were monitored (ClinicalTrials.gov NCT03738787).
Results: Fifty-one patients underwent PDO and 49 PJA. DCC 3, postoper-
ative mortality, and POPF grade B-C were 25.5% versus 24.5% (P ¼ 0.91),
5.9% versus 2% (P ¼ 0.62), and 11.8% versus 16.3% (P ¼ 0.51) in the study
versus control cohort, respectively. At 1 and 3 years, new-onset diabetes was
diagnosed in 13.7% and 36.7% of the study cohort versu 4.2% and 12.2% in
controls (P ¼ 0.007).
Conclusions: PDO with neoprene-based glue is a safe technique that equal-
izes early outcome of selected patients at high risk of POPF to those at low risk
undergoing PJA. Neoprene-based PDO, however, triples the risk of diabetes at
1 and 3 years.
Keywords: neoprene, pancreatic duct occlusion, pancreatic fistula,
pancreatic stump, pancreatoduodenectomy
(Ann Surg 2019;270:791–798)
I n 1935, Allen Whipple first described the pancreatoduodenectomy(PD)1: an operation that remains burdened by significant morbid-
ity, mainly related to postoperative pancreatic fistula (POPF).2 The
incidence of POPF is 5% to 30%3 and pancreatic texture, diameter
and position of Wirsung duct, blood loss, body mass index (BMI),
and pancreatic disease etiology are the identified risk factors.4 No
technique has proven to be superior to others in avoiding this
complication.5–7
In the 1980s, pancreatic duct occlusion (PDO) was explored as
alternative to pancreaticojejunal anastomosis (PJA). Among other
compounds, the neoprene latex – a polychloroprene homopolymer
with a natural pH of 12, low viscosity and heat resistance – was
tested in clinical trials.8,9 Peculiar of neoprene latex is the ability to
depolymerize in contact with the basic pH of the pancreatic juice,
hardening into a semisolid cast of the Wirsung duct. Despite these
attractive features, the scientific evidence of neoprene-based PDO
efficacy is lacking.8,10–14
In our practice, we have continued to consider PDO with
neoprene in life-threatening post-Whipple reoperations, aiming to
control severe pancreatic fistulas and avoid total pancreatectomy.
The present prospective study was designed to investigate under
standardized conditions safety and efficacy of neoprene-based PDO
in a selected group of PD at high risk of POPF.
METHODS
Study Design
This is a single-center, prospective, nonrandomized, parallel
cohort study, (NCT03738787) designed to assess safety and efficacy
of stabilized neoprene-based glue (Pancreas-Lock, SALF Pharma,
Cenate Sotto, BG, Italy) for intraoperative occlusion of the pancre-
atic remnant after PD.
The trial design is summarized in Figure 1.
The study enrolled 100 patients undergoing radical PD for
various cancers of the pancreaticoduodenal region from
January 2015 to December 2017. After tumor and pancreatic head
removal, patients with a fistula risk score (FRS)4 >15% (6 points)
were considered at high risk for POPF and thus treated with PDO
using neoprene glue (study cohort). A parallel cohort of control
patients who were operated on during the same period and considered
at low risk of POPF (FRS 15%: 5 points) received conventional
pancreatic-jejunal reconstructions (control cohort).
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The primary endpoint of the study was to compare in the 2
cohorts the 30-day complication rate according to Dindo-Clavien
Classification (DCC)15. Secondary endpoints of the study were the
evaluation of new-onset insulin-dependent diabetes along the follow-
up and patients survival outcomes. For the evaluation of secondary
endpoints, the study cohort also included those controls who required
relaparotomy because of an unmanageable pancreatic fistula and
were rescued from total pancreatectomy by means of PDO with
neoprene-based glue (rescued patients).
Technical Aspects and Definitions
All patients underwent open pancreatoduodenectomy.
Lymphadenectomy was performed according to the International
Study Group on Pancreatic Surgery (ISGPS) recommendations.16
The FRS was assessed intraoperatively through a calculator4 taking
into account gland texture, Wirsung diameter (measured with a
ruler), blood loss, and histology. In the study cohort, a 16G-18G
catheter was inserted as distal as possible into the pancreatic duct of
the remnant pancreas and slowly retracted while injecting 5 to 15 mL
of neoprene glue. About 10 minutes were allowed for glue hardening,
before completing the stump closures with a continuous polypropyl-
ene suture. In patients undergoing conventional reconstruction, duct-
to-mucosa (22 cases: 44.8%) or double-layer PJA (27 cases: 55.2%)
was adopted according to intraoperative conditions, leaving an
internal drainage catheter into the pancreatic duct.17 At the end of
surgery, 2 passive drains were placed. Amylase level from drainage
fluid was assessed on day 1, 3, 5, and thereafter if clinically indicated.
Drains were removed on postoperative day 7 unless clinically
contraindicated.
ISGPS definition of pancreatic fistula was used, that is, any
drain fluid on or after postoperative day 3 with amylase level >3
times the upper normal limit (100 U/L). Fistula diagnosis was applied
only to B-C grade.2,18 Postoperative complications were assessed
using Dindo-Clavien classification17 and Comprehensive Complica-
tion Index.19
Follow-Up Schedule and Metabolic evaluation
Before surgery and during follow-up at 1, 3, 6, and 12 months
all enrolled patients underwent clinical and physical examination,
standard laboratory tests, and assessment of antidiabetic drugs use.
Metabolic status was assessed by fasting glycemia, glycosylated
hemoglobin, C-peptide, fasting insulin, and Homeostasis Model
Assessment (HOMA) insulin resistance index before surgery and
at the end of follow-up.20 Total cholesterol, triglycerides, low-density
lipoprotein cholesterol, and high-density lipoprotein cholesterol
(HDL-C) were also measured. Patients were defined diabetics if
they had history of type II diabetes mellitus or if they met standard
criteria.21
Statistical Methods
The study was conducted according to a Gehan design22 in
which the first part was replaced by a 2-stage Simon scheme,
determining upfront the maximum number of patients suffering
severe complications after PDO which would have suffice study
interruption (Fig. 1).23,24 The null hypothesis would have been
rejected whether the complication rate according to DCC 3 was
0.4 in the first 20 patients. The enrolment of 7 and 13 patients was
required, being 4 and 9, respectively, the number of patients with
DCC 3 justifying study interruption. This design has a type I error
of 0.045 and a power of 0.81 when the true proportion of responses is
0.7. After the DCC3 complication rate was deemed acceptable, the
recruitment continued prospectively.
Continuous variables are presented as median (1st–3rd quar-
tile) and compared using Pearson rank analysis. Categorical variables
are presented as absolute numbers and percentages. Baseline char-
acteristics are compared using the Student t test, chi-square test, or
Fisher exact test, as appropriate. Follow-up time was calculated by
means of reverse Kaplan–Meier method. Time-to-event curves were
calculated with the Kaplan–Meier method and compared by the log-
rank test. Overall survival was calculated from the date of surgery
to the date of death from any cause or the date of last follow-up.
Non–cancer-specific survival was calculated from the date of sur-
gery to the date of death for nontumoral events, censoring for patients
deceased for tumor recurrence or alive at last follow-up. Statistical
analyses were conducted using SPSS (version 20.0). A 2-sided
P < 0.05 was considered statistically significant.
RESULTS
The study cohort included 51 patients at high risk for POPF
who underwent PDO with neoprene-based glue. During the same
period, 49 patients at low risk for POPF underwent PD with PJ
anastomosis (controls).
Baseline and intraoperative characteristics of the 2 popula-
tions are summarized in Table 1. The 2 cohorts were similar for most
clinical characteristics, with the exception of baseline albumin levels
(lower in the study cohort, P¼ 0.04) and tumor stage, more advanced
in the study group receiving PDO with respect to controls; notably,
these are factors that per-se are associated with higher risk of POPF
regardless the FRS score. A significant higher number of patients
with metastatic lymph nodes was in fact detected in the PDO group
FIGURE 1. Study flowchart and main outcomes.
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(P ¼ 0.022). A median of 8.5 mL (7–11) of neoprene-based prepa-
ration was injected in the pancreatic stump of the study cohort. No
significant differences in terms of operative time and transfusions
were registered between cohorts. As per study design, fistula risk
score was significantly higher in the study cohort (median 22 vs 6;
P < 0.001).
Primary Outcome Measures
The median follow-up time of the study versus control cohorts
was 15 (9–26) versus 21 (11–39) months (P ¼ 0.6); no patient was
lost at follow-up.
Postoperative outcomes are shown in Table 2. Complications
described as DCC 3 at 30 days (primary endpoint) occurred in 13
patients (25.5%) of the study cohort and in 12 (24.5%) controls
(P ¼ 0.91). Overall complication rate (DCC: 1–5) was 56.9% (29
patients) in the study cohort and 55.1% (27 patients) in controls
(P ¼ 0.86). The most common complication in both cohorts was
delayed gastric emptying (15.7%–18.4%), followed by POPF grade
B-C in the control cohort (16.3%) and pleural effusion in the study
cohort (15.7%) (Fig. 2). No adverse event directly correlated with
neoprene glue PDO was observed. In particular, the rate of chemical
pancreatitis was 0%, even in those who underwent rescue PDO.
No difference between cohorts was observed in terms of
reoperations (13.7% vs 16.3%, P ¼ 0.72), hospital stay (13 vs 15
days, P ¼ 0.61) and readmission rate. No patients in both cohorts
underwent total pancreatectomy, as 7 controls required reoperation
(14.3%) and were rescued successfully with neoprene duct occlusion
and takedown of the PJ anastomosis.
TABLE 1. Baseline Characteristics of 2 Cohorts of Patients Undergoing Pancreatoduodenectomy at Different Risk of POPF
High Risk of POPF Neoprene PDO (n ¼ 51) Low Risk of POPF PJ Anastomosis (n ¼ 49) P
Age, y 68 (62–75) 65 (57–71) 0.24
Sex (male) 28 (54.9%) 26 (53.1%) 0.85
BMI, kg/m2 24 (22–26) 24 (22–26) 0.83
Preoperative diabetes 13 (25.5%) 11 (22.5%) 0.72
Liver cirrhosis 3 (5.9%) 0 0.24
ASA score 0.47
1 0 4 (8.2%)
2 40 (78.4%) 35 (71.4%)
3 11 (21.6%) 9 (18.4%)
4 0 1 (2.0%)
Albumin level, g/dL 4.0 (3.8–4.3) 4.2 (3.9–4.5) 0.04
Blood glucose, mg/dL 106 (91–126) 106 (93–124) 0.87
Insulin level, mU/mL 6.9 (4.8–9.5) 8.4 (6.0–12.5) 0.75
C-peptide, ng/mL 2.4 (1.7–3.3) 2.5 (1.7–2.9) 0.14
Total cholesterol, mg/dL 169 (149–193) 183 (152–218) 0.24
HDL 49 (40–61) 50 (35–55) 0.45
LDL 80 (56–104) 124 (80–134) 0.03
Triglycerides, mg/dL 90 (72–115) 89 (73–149) 0.52
Preoperative HOMA score 1.68 (1.35–3.08) 1.88 (1.21–3.48) 0.51
Neoadjuvant 0.15
Chemotherapy 9 (15.8%) 4 (8.2%)
Radiotherapy 1 (2%) 0
Preoperative 0.43
ERCP stenting 20 (39.2%) 23 (46.9%)
PTBD 2 (3.9%) 3 (6.1%)
Tumor histology 0.38
PDAC 33 (64.7%) 32 (65.3%)
BDAC 8 (15.7%) 6 (12.2%)
PapAC 5 (9.8%) 4 (8.2%)
DuodAC 4 (7.8%) 2 (4.1%)
pNET 1 (2.0%) 5 (10.2%)
Lymph node status 0.016
Negative 14 (27.5%) 26 (53.1%)
Positive 37 (72.5%) 23 (46.9%)
Intraoperative characteristics
Operative time, minutes 480 (400–553) 490 (438–540) 0.78
Neoprene injection, mL 8.5 (7–11) 0
Blood loss, mL 200 (100–200) 200 (100–200) 0.77
Fistula Risk Score 22% (18–25%) 6% (6–9%) <0.001
FRS class (points) <0.001
Negligible (0) 0 (0%) 0 (0%)
Low (1–2) 0 (0%) 34 (69.4%)
Intermediate (3–6) 14 (27.4%) 14 (28.6%)
High (7–10) 37 (72.6%) 1 (2.0%)
Vascular resection 7 (13.7%) 6 (12.2%) 1
Numbers are presented as absolute numbers (%) or medians (interquartile range). ASA indicates American Society of Anesthesiologists; BDAC, biliary duct adenocarcinoma; BMI,
Body Mass Index; DuodAC, adenocarcinoma of duodenum; ERCP, endoscopic retrograde cholangio-pancreatography; PapAC, adenocarcinoma of the papilla; pNET, pancreatic
neuroendocrine tumor; PTBD, percutaneous transhepatic biliary drainage.
Subgroup analysis did not show significant differences with respect to patients, tumor stage and operation characteristics among neoadjuvant-receiving vs naı¨ve patients.
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All postoperative-related deaths occurred within 30 days from
surgery and no difference in 90 days’ mortality was observed between
cohorts (P¼ 0.62). In details, 3 patients died in the study cohort (5.9%)
because of intracranial bleeding, liver insufficiency, and sepsis,
whereas 1 control died (2.0%) because of postoperative bleeding
and multiorgan failure. As no worsening in morbidity and mortality
was observed after duct occlusion in patients at high risk of POPF
with respect to the parallel cohort at low risk of fistula receiving PJA,
the efficacy of duct occlusion with neoprene was confirmed.
Secondary Outcome Measures
Non–cancer-specific survival at 1 and 3 years (Fig. 3A,
continuous lines) did not differ among groups (98% and 98% in
the study cohort vs 94.1% and 91.1% in controls: P ¼ 0.7).
Conversely, overall survival (Fig. 3 A, dotted lines) reflected the
more advanced tumor stage observed in PDO (1- and 3-year survival:
73.9% and 34.1% in the study cohort vs 86.8% and 64.4% in the
control cohort, P ¼ 0.009).
At baseline no difference in terms of BMI (24 vs 24 kg/m2),
preoperative diabetes (13 vs 11 patients), fasting blood glucose levels
(106 vs 106 mg/dL), insulin level (6.9 vs 8.4mU/mL) C-peptide (2.4
vs 2.5 ng/mL), HOMA (1.68 vs 1.88), triglycerides, and total cho-
lesterol was found in the 2 cohorts. Only preoperative LDL choles-
terol was slightly higher in the control cohort (80 vs 124 mg/dL, P ¼
0.03).
Figure 3B reports the risk curve for new-onset diabetes: at 1
and 3 years diabetes occurred in 13.7% and 36.7% in the study cohort
and 4.2% and 12.2% in the control cohort (P¼.007). Post-neoprene-
TABLE 2. Perioperative Outcomes After Pancreatoduodenectomy in the 2 Patient cohorts Under Study
High Risk of POPF Neoprene PDO (n ¼ 51) Low Risk of POPF PJ Anastomosis (n ¼ 49) P
Patients receiving blood cell transfusion 8 (15.7%) 7 (14.3%) 0.84
Patients with uneventful course 22 (43.1%) 22 (44.9%) 0.86
30 Days’ overall postoperative morbidity 29 (56.9%) 27 (55.1%) 0.86
30 Days’ DCC  3 morbidity 13 (25.5%) 12 (24.5%) 0.91
Comprehensive Complication Index 20.9 (0.0–34.2) 20.9 (0.0–33.5) 0.61
POPF 6 (11.8%) 8 (16.3%) 0.51
Grade B 5 (9.8%) 3 (6.1%)
Grade C 1 (2.0%) 5 (10.2%)
Postoperative complications 0.86
Surgical site infection 5 (9.8%) 2 (4.1%)
Pneumonia 1 (2.0%) 2 (4.1%)
Pleural effusion 8 (15.7%) 7 (14.3%)
Cardiological complications 2 (3.9%) 2 (4.1%)
Neurological complications 1 (2.0%) 1 (2.0%)
Bleeding 7 (13.7%) 5 (10.2%)
Biliary fistula 4 (7.8%) 7 (14.3%)
Intra-abdominal abscess 4 (7.8%) 2 (4.1%)
Lymphatic fistula 2 (3.9%) 2 (4.1%)
Delayed gastric empting 8 (15.7%) 9 (18.4%)
Postoperative pancreatitis 0 (0%) 0 (0%)
Maximum DCC grade of complication 0.81
1 3 (5.9%) 1 (2.0%)
2 12 (23.5%) 14 (28.6%)
3 9 (17.6%) 10 (20.4%)
4 2 (3.9%) 1 (2.0%)
5 3 (5.9%) 1 (2.0%)
Reoperation 7 (13.7%) 8 (16.3%) 0.72
Cause of reoperation
Bleeding 4 (7.8%) 4 (8.2%)
Biliary fistula 2 (3.9%) 3 (6.1%)
Pancreatic fistula 0 (0%) 4 (8.2%)
Bowel perforation/dehiscence 3 (5.9%) 0 (0%)
Wound dehiscence 0 (0%) 1 (2.0%)
Salvage Neoprene duct occlusion – 7 (14.3%)
Length of hospital stay 16 (13–25) 15 (13–24) 0.61
Readmission rate 3 (6.0%) 0 (0.0%) 0.24
Cause of readmission
Dehydration (ileostomy) 1 (2.0%) 0 (0%)
Fistula drain reposition 1 (2.0%) 0 (0%)
Wound infection 1 (2.0%) 0 (0%)
90 Days’ mortality 3 (5.9%) 1 (2.0%) 0.62
Cause of death
Intracranial haemorrhage 1 (2.0%) 0 (0%)
Liver failure 1 (2.0%) 0 (0%)
Sepsis 1 (2.0%) 0 (0%)
Intra-abdominal haemorrhage 0 (0%) 1 (2.0%)
Numbers are presented as absolute numbers (%) or medians (interquartile range).
Diabetic induced treatment was not different between groups when excluding from calculation the 7 nondiabetic patients who received rescued PDO. However, the rate of new-
onset diabetes at 3 years was 23.8% vs 12.2% (P ¼ 0.04) in the study vs control cohort, respectively.
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induced diabetes required insulin treatment in the long-term in 58.3%
of cases, whereas both patients with new onset post-PJ anastomosis
become insulin-dependent. Also, a significant difference in median
C-peptide and blood glucose level was detected in favor of controls
[0.84 vs 1.3mU/mL (P ¼ 0.009) and 117 vs 95.5 mg/dL (P ¼ 0.002)
in study vs control cohort, respectively]. A trend toward higher
blood glucose levels and more pronounced weight loss in the study
cohort was observed along the follow-up (Supplementary Fig. 1,
http://links.lww.com/SLA/B718), during which no significant differ-
ence was found in BMI, insulin level, cholesterol and triglycerides. In
the surviving patients, median HOMA ratio variations from surgery
to the end of 20 months follow-up were67.3% (75.3%; 55.1%) in
the study cohort and 26.7% (71.4%; 20.2%) in controls, with no
statistical difference (P¼ 0.803) found (Supplementary Fig. 2, http://
links.lww.com/SLA/B718).
DISCUSSION
Technical and perioperative advancements have reduced the
mortality rate after pancreatoduodenectomy below 2% to 5%.25
However, complications requiring surgical, endoscopic, or radiolog-
ical intervention (Dindo-Clavien grade3) remain as high as 30% to
40%, mainly attributable to the onset of pancreatic fistula.26,27–30
The results of the present prospective series of 100 consecutive PD
are in line with those general figures (Table 2), whereas differ on
offering pancreatic-duct occlusion with neoprene glue to patients at
significant risk for POPF (FRS >15%: 6 points). Notably, about
half of the collected patients were at high risk of fistula and 27% had
a borderline risk (FRS¼ 6 points) considered eligible to the neoprene
glue duct occlusion. These rates are higher than in previous stud-
ies4,31 and that might be partly explained by the selection of several
unfavorable conditions for PJ-anastomosis (ie, nonadenocarcinoma
FIGURE 2. Postoperative complications. Rates of general complications, DCC 3 complications, and clinically relevant pancreatic
fistula are summarized. No significant difference was observed between cohorts (primary endpoint).
A B
FIGURE 3. Postoperative outcomes. (A) Non–cancer-specific survival (continuous lines) and overall survival (dotted lines) in the 2
study cohorts. (B) Cumulative risk of developing new-onset diabetes in patients with no stigmata of diabetes at the time of surgery.
The prognosis of pancreatoduodenectomy ismainly tumor-related. Duct occlusionwith neoprene glue helps to overcome safely the
early postoperative period in patients at high risk of pancreatic fistula, although does not protect against cancer-related outcome
and is followed by increased occurrence of long-term diabetes.
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tumors: 35%, previous major surgery: 18%, low-albumin and liver
cirrhosis: 6%, chronic pancreatitis: 0%).
Management of the remnant pancreas after PD remains prob-
lematic, with no criterion standard available.5–7,32 Closure of the
pancreatic remnant after PD has been repeatedly proposed and
several studies compared PJ anastomosis with stump closure by
various Wirsung-occluding materials.9,27,33–37 All these studies and
1 randomized controlled trial (RCT) failed to demonstrate a signifi-
cant advantage of stump closure over conventional pancreatic-enteric
anastomosis, turning the PDO into an abandoned practice. That
appears unjustified considering the suboptimal patients selection
of previous studies.
Above all, the practice of neoprene duct occlusion has per-
sisted in case of severe fistula requiring relaparotomy, to rescue
the pancreatic remnant and avoid total pancreatectomy associated
with a mortality >40%.38–40 As described in Figure 1 and Table 2,
in the presented study rescue PDO with neoprene glue occurred in
7 patients, without observing any associated mortality.
In rescue settings or in case of high-risk of fistula, total
pancreatectomy with autologous islet transplantation can be a prom-
ising alternative to control post-surgical diabetes, although <20% of
insulin independence is expected in the long term.41,42
The innovative characteristics of the present prospective study
rely on the predetermined intraoperative identification of PD at high
risk of fistula as the subgroup eligible to duct occlusion, without any
attempt of PJ anastomosis. The risk of POPF was defined by factors
widely recognized as weak points for restoring pancreatic-digestive
continuity.4,43 Of note, in this study also patients with a FRS score of
6 – at the upper boundary of the intermediate risk class4 – were
considered at high risk of POPF and included in the occlusion cohort,
anticipating a potential benefit from the technique also in interme-
diate-risk conditions. The study resulted in a nonsignificant differ-
ence in postoperative outcome among 2 parallel cohorts of patients at
different risk of POPF. Therefore, the primary endpoint was met
(Fig. 2), confirming the neoprene glue as an easy, safe, and reliable
device able to replace PJA in patients at high risk for POPF.
Notably, the observed neoprene-associated complication rate
was lower than in large series of patients with elevated FRS undergoing
PJ anastomosis (ie, overall complication rate: 56.9% vs 77.4%; DCC
3: 25.5% vs 35.6%, clinically relevant fistulae: 11.8% vs 29%).44,45
As previously described, the incidence of postsurgical new-
onset diabetes was higher in neoprene-PDOs with respect to the PJ-
anastomosis cohort (Fig. 3B). Most likely, neoprene-induced fibrosis
was responsible for a significant reduction of the preoperative versus
postoperative levels of insulin and C-peptide in neoprene-occluded
patients with respect to controls (P ¼ 0.035 and <0.001, respec-
tively), noting however that presurgical borderline glucose and
C-peptide conditions were more frequent in nondiabetic neoprene-
treated versus control patients (Table 1), in agreement with previous
reports.
As expected, the long-term patients’ survival was mainly
related to tumor histology and stage, which were significantly more
advanced in the neoprene PDO patients (Table 1). As previously
described, more advanced locoregional cancer stages in the pan-
creatoduodenal region are associated with complex PD procedures
and high risk of fistula in case of pancreaticoenteric anastomosis.46
When survival analysis was restricted to non–cancer-related
death (Fig. 3A), no difference in survival was observed between
neoprene-treated versus control patients. This is in favor of pancre-
atic-duct occlusion in patients with locally advanced cancer requiring
complex procedures. In such a subgroup of risky PD the use of
neoprene PDO may equalize the early outcome of such a population
in need of adjuvant treatment to that of patients undergoing PJA
under standardized conditions.
The present study has limitations related to the relatively small
sample size and to the non-random, although prospective, fashion
design. Should the use of neoprene glue be rejuvenated after the
present demonstration of safety and efficacy, prospective RCT may
be redefined, focusing on the specific subgroup of patients at high
risk of POPF. Finally, the heterogeneity of indications to PD and lack
of specific monitoring impede to draw any conclusions on long-term
impact of PDO on pancreatic exocrine insufficiency.
In conclusion, PDO with neoprene-based glue is safe and
potentially efficacious. This technique can replace anastomosis in
patients at high risk of POPF and avoid total pancreatectomy in the
emergency setting. On the downside, this technique triples the 1- and
3-year risk of new-onset diabetes.
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DISCUSSANTS
Jose´ M.R. Angel (Guadalajara, Spain):
First, I want to thank the ESA Scientific Committee for
allowing me to comment on the work of Prof. Mazzaferro and his
co-workers.
The article deals with a very interesting topic for pancreatic
surgeons, which is an approach for avoiding a pancreatic fistula after
a PD in high-risk fistula patients using neoprene glue occlusion.
The study has a nice methodology. First, they have demon-
strated the facts and safety of the technique, before comparing duct
occlusion in high-risk patients with PJA in non-low-risk patients.
My main concern is that they used a fistula rate score cut-off
that differs from Callery et al. In my opinion, a pure RCT would be
more powerful than a prospective study.
So, I have 2 questions:
First, could you please explain the reasons behind your
decision to modify the cut-off of FRS?
Second, why did you not perform a pure RCT after checking
the safety?
Response From Vincenzo Mazzaferro (Milan, Italy):
Thank you for your comments. With respect to the first
question, we included point 6 of the fistula risk score – and declared
that upfront – because we wanted to be more inclusive in the
population at risk of a fistula, in case of a difficult Whipple
operation. After all, the patients with 6 points consisted of about
27% of the whole series. This is slightly above the standard, but not
significantly different from those patients with a score >8. In my
opinion, this series presented a more evident bias in the selection,
represented by a lack of general conditions favoring PJ-anastomo-
sis, such as the absence of chronic pancreatitis and high rate of
nonadenocarcinoma tumors, previous major surgery, and the pres-
ence of liver cirrhosis.
With respect to the randomized control trial, the aims of our
study were as follows: to rejuvenate an almost abandoned technique;
to find the best setting for a patient’s condition, to offer duct
occlusion; and to plan a randomized control study, after having
demonstrated the safety and effectiveness of the technique. Looking
at the results of the presented study, a randomized control trial can be
proposed with a noninferiority design, which compares PDO with
neoprene-based glue versus conventional PJ reconstruction in
patients at a high risk of a post-duodenopancreatectomy fistula,
and especially, in those with locoregional advanced cancer.
Antonio D. Pinna (Abu Dhabi, United Arab
Emirates):
I have 2 very short questions. First of all, I would have liked
you to compare the neoprene with the PJA in a comparable patient
population. Second, neoprene has shown higher cancer-related mor-
tality compared to the other group. One-third of the patients also had
diabetes. Do you think that the neoprene-treated patients would
actually have been better candidates for a total pancreatectomy?
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Response From Vincenzo Mazzaferro (Milan, Italy):
The patients who were given neoprene duct occlusion were
selected after an intraoperative determination of their high risk of
postoperative fistula. Before starting this prospective study, we had
the experience of using neoprene as a salvage procedure in patients
with severe post-Whipple leaks who – thanks to the neoprene glue –
were rescued and avoided a total pancreatectomy. Hence, we thought
that the best comparator for neoprene duct occlusion were the
patients at a high risk of fistula, rather than the general population
or those with a good predicted result of PJ anastomosis. This was
incorporated into the presented prospective study design.
With respect to the correlation between duct occlusion and
cancer-related mortality, this was related to the fact that the number
of patients with positive lymph nodes made up 75% of the patients in
the neoprene-treated group versus 20% to 25% in the anastomosis
group. This was a sort of inverse selection bias, which favored duct
occlusion in patients with more advanced cancer and diabetes. I don’t
know whether these were truly candidates for total pancreatectomies.
For sure, the local advancement of cancer implied extensive dissec-
tion, blood loss, pancreatic gland manipulation, and ultimately, the
inclusion of more of these patients in the duct occlusion group.
Christiane Bruns (Cologne, Germany):
I have 3 questions regarding the oncological outcome. As I
understood, you decided on neoprene-based glue injection in the
pancreatic duct intraoperatively. Did you also analyze the pancreatic
resection margin through intraoperative frozen sections? Did you
include patients in the study, in whom you had to perform a vascular
resection? Third, which kind of anastomotic technique did you use
for the pancreatojejunostomy?
Response From Vincenzo Mazzaferro (Milan, Italy):
No, we did not use any oncological marker or margin assess-
ment to make a final decision on duct occlusion. The final decision
was based on the pancreatic fistula score, which included blood loss,
the texture of the pancreatic gland, the size of the Wirsung duct, and
pancreatic/biliary versus ampullary/duodenal cancer.
The number of vascular reconstructions was similar in both
groups. In fact, this did not influence the decision of whether we
should use the glue.
With respect to the technique of conventional reconstruction,
duct-to-mucosa or double-layer PJ anastomosis was adopted accord-
ing to intraoperative conditions. According to the numbers, about
half of the patients were included in each of these 2 alternatives.
Pierre-Alain Clavien (Zurich, Switzerland):
Thank you, Dr. Mazzaferro, for presenting this provocative
study at the ESA, which expectedly triggers an animated discussion. I
have 2 questions. First, this procedure consistently resulted in
disasters not a long time ago. Am I correct? Consequently, any
attempt at occluding the Wirsung duct was abandoned in favor of a
total pancreatectomy, when a PJA was not suitable. So, what are you
really doing differently? Please, tell us why this is now suddenly
successful.
Next, you showed us 2 risk groups, and chose to perform the
glue approach in the group with the highest risk and the standard
anastomosis in the one with the lowest risk. Yet, you obtained quite
similar results in the glue group, despite the presence of much higher
risk factors. If we follow this logic, and challenge you a little bit, why
should we continue performing anastomoses, rather than just sim-
plifying the procedure by injecting glue into all patients? Are you
ready to complete a RCT, which would include all patients irre-
spective of the degree of risk?
Response From Vincenzo Mazzaferro (Milan, Italy):
Thank you for your provocative questions. As expected, the
group of patients with a low risk of fistula had a better outcome. They
had a lower incidence of diabetes, reduced weight loss, better
performance status, and so on. So, patients in the PJA were favored
in the long run. This is clear from the data, confirming that conven-
tional anastomosis should be pursued whenever possible. However,
in particularly difficult procedures correlated with high-risk con-
ditions, duct occlusion is an alternative that can be used safely and
effectively. Because of neoprene glue duct injection, 2 very different
postoperative outcomes may be equalized into a more predictable
and lower-risk status, which allows better in-hospital performance
after a pancreatoduodenectomy. I’m not saying that we have to
replace PJA with duct occlusion. Conversely, our study demonstrates
that a subgroup of least favorably placed patients can be rescued with
a simple, inexpensive technique, which is able to return them to a
standard postoperative period at a low risk of serious complications.
As mentioned above in my reply to Professor Ramia Angel, I
do not think that a RCT, which includes all patients irrespective of the
degree of fistula risk, is justified. Conversely, a noninferiority trial
comparing neoprene duct occlusion vs. conventional PJ anastomosis
in patients at a high risk of fistula is well supported by the result of the
present prospective study.
Melina Kibbe (Chapel Hill, NC):
I actually do think that you need to perform this trial in the
high-risk group. My question is very basic. Why are you using
neoprene glue? Why aren’t you using more of a biologic? This is like
rubber that you’re putting in there. So, why neoprene when there are
many biologic options out there?
Response From Vincenzo Mazzaferro (Milan, Italy):
We work in the laboratory with our faculty of chemistry in
modifying the neoprene glue with respect to previous formulations.
The glue used in this study has a peculiar characteristic with respect
to biological, expensive materials, in that the neoprene latex is a low-
viscosity, milky fluid that depolymerizes in contact with the basic pH
of the pancreatic juice, hardening into a semisolid cast of the Wirsung
duct in front of the surgeon’s eyes within a few minutes.
Although duct occlusion with this material is a pure surgical,
hand-guided maneuver, the neoprene glue maintains sophisticated
characteristics, which, with respect to biologic materials (data not
shown), allows a predictable and permanent effect. It allows us to
avoid a total pancreatectomy.
Mazzaferro et al Annals of Surgery  Volume 270, Number 5, November 2019
798 | www.annalsofsurgery.com  2019 The Author(s). Published by Wolters Kluwer Health, Inc.
